{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T03:58:36Z","timestamp":1790222316264,"version":"4.1.0"},"reference-count":13,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2025,11,22]],"date-time":"2025-11-22T00:00:00Z","timestamp":1763769600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,2,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>The objective of this study was to characterize the risk of myositis after Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)\u00a0vaccination with messenger ribonucleic acid (mRNA) or adenoviral vector vaccines.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We conducted a population-based cohort study in Norway and Sweden of 13 million persons who turned 12\u2009years or older in 2021 and were residents at the start of follow-up on 27 December 2020. The participants were followed until incident diagnosis of myositis, censoring, or the end of the study (21 May 2023). We used Poisson regression to estimate incidence rate ratios (IRRs) with 95% CIs, comparing rates in risk periods (day 0 up to and including day 180 after each dose) with rates in unvaccinated periods. Corrections for potential confounding were made by adjusting for sex, age, occupation (health-care worker), region, positive COVID-19 test, and comorbidities.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>We observed 101 myositis events in 7\u2009002\u2009398 unvaccinated person-years and 99 myositis events within 180\u2009days of any combination of mRNA vaccines (6\u2009241\u2009529 person-years), and 13 with the adenoviral vector vaccine (445\u2009256 person-years). The adjusted IRRs for the 180-day risk periods following any combination of mRNA vaccines and the adenoviral vector vaccine were 0.84 (95% CI, 0.63\u20131.11) and 1.31 (0.72\u20132.36), respectively, compared with unvaccinated periods. The estimates for each specific first, second and third dose of mRNA were similar to the estimate of all doses combined.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>In this nationwide study of &amp;gt;13.6 million person-years in two countries, there were no signs of an increased risk of myositis after SARS-CoV-2 vaccination, neither after the mRNA vaccines nor after the adenoviral vector vaccine.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/rheumatology\/keaf609","type":"journal-article","created":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T13:27:57Z","timestamp":1763731677000},"source":"Crossref","is-referenced-by-count":3,"title":["SARS-CoV-2 vaccination and myositis in Norway and Sweden"],"prefix":"10.1093","volume":"65","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0654-4530","authenticated-orcid":false,"given":"Rickard","family":"Ljung","sequence":"first","affiliation":[{"name":"Pharmacoepidemiology and Analyses Department, Swedish Medical Products Agency , Uppsala,","place":["Sweden"]},{"name":"Institute of Environmental Medicine, Karolinska Institutet , Stockholm,","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6812-0971","authenticated-orcid":false,"given":"Nicklas","family":"Pihlstr\u00f6m","sequence":"additional","affiliation":[{"name":"Pharmacoepidemiology and Analyses Department, Swedish Medical Products Agency , Uppsala,","place":["Sweden"]},{"name":"Institute of Environmental Medicine, Karolinska Institutet , Stockholm,","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0369-9393","authenticated-orcid":false,"given":"Jesper","family":"Dahl","sequence":"additional","affiliation":[{"name":"Norwegian Institute of Public Health , Oslo,","place":["Norway"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1770-1183","authenticated-orcid":false,"given":"German","family":"Tapia","sequence":"additional","affiliation":[{"name":"Norwegian Institute of Public Health , Oslo,","place":["Norway"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2337-3371","authenticated-orcid":false,"given":"Anders","family":"Sundstr\u00f6m","sequence":"additional","affiliation":[{"name":"Pharmacoepidemiology and Analyses Department, Swedish Medical Products Agency , Uppsala,","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marja-Leena","family":"Nurminen","sequence":"additional","affiliation":[{"name":"Pharmacoepidemiology and Analyses Department, Swedish Medical Products Agency , Uppsala,","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6068-9212","authenticated-orcid":false,"given":"Ingrid E","family":"Lundberg","sequence":"additional","affiliation":[{"name":"Medical Unit of Gastroenterology, Dermatology and Rheumatology, Karolinska University Hospital , Stockholm,","place":["Sweden"]},{"name":"Division of Rheumatology, Department of Medicine, Solna, Karolinska Institutet , Stockholm,","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1204-787X","authenticated-orcid":false,"given":"\u00d8ystein","family":"Karlstad","sequence":"additional","affiliation":[{"name":"Norwegian Institute of Public Health , Oslo,","place":["Norway"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8996-5260","authenticated-orcid":false,"given":"Marie","family":"Holmqvist","sequence":"additional","affiliation":[{"name":"Medical Unit of Gastroenterology, Dermatology and Rheumatology, Karolinska University Hospital , Stockholm,","place":["Sweden"]},{"name":"Clinical Epidemiology Division, Department of Medicine Solna, Karolinska Institutet , Stockholm,","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1460-4078","authenticated-orcid":false,"given":"Nils","family":"Feltelius","sequence":"additional","affiliation":[{"name":"Pharmacoepidemiology and Analyses Department, Swedish Medical Products Agency , Uppsala,","place":["Sweden"]},{"name":"Department of Public Health and Caring Sciences, Uppsala University , Uppsala,","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,11,22]]},"reference":[{"key":"2026022605570754800_keaf609-B1","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1093\/rheumatology\/kew503","article-title":"Incidence and prevalence of idiopathic inflammatory myopathies in Sweden: a nationwide population-based study","volume":"56","author":"Svensson","year":"2017","journal-title":"Rheumatology (Oxford)"},{"key":"2026022605570754800_keaf609-B2","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1001\/jamadermatol.2022.3112","article-title":"Incidence of dermatomyositis in a nationwide cohort study of US Veterans","volume":"158","author":"Bolender","year":"2022","journal-title":"JAMA Dermatol"},{"key":"2026022605570754800_keaf609-B3","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1007\/s12026-023-09368-2","article-title":"COVID-19 vaccine-associated myositis: a comprehensive review of the literature driven by a case report","volume":"71","author":"Syrmou","year":"2023","journal-title":"Immunol Res"},{"key":"2026022605570754800_keaf609-B4","doi-asserted-by":"crossref","first-page":"1013378","DOI":"10.3389\/fmed.2022.1013378","article-title":"A case series of dermatomyositis following SARS-CoV-2 vaccination","volume":"9","author":"Chan","year":"2022","journal-title":"Front Med (Lausanne)"},{"key":"2026022605570754800_keaf609-B5","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1016\/j.neurol.2022.11.009","article-title":"Immune-mediated necrotizing myopathy following vaccination with the AstraZeneca (AZD1222) COVID-19 vaccine: a case report and brief review","volume":"179","author":"Ansari","year":"2023","journal-title":"Rev Neurol (Paris)"},{"key":"2026022605570754800_keaf609-B6","doi-asserted-by":"crossref","DOI":"10.4081\/reumatismo.2023.1548","article-title":"Idiopathic inflammatory myopathies linked to vaccination against SARS-CoV-2: a systematic review","author":"Camargo-Coronel","year":"2023","journal-title":"Reumatismo"},{"key":"2026022605570754800_keaf609-B7","doi-asserted-by":"crossref","first-page":"1007637","DOI":"10.3389\/fpubh.2022.1007637","article-title":"Inflammatory myopathy following coronavirus disease 2019 vaccination: a systematic review","volume":"10","author":"Ding","year":"2022","journal-title":"Front Public Health"},{"key":"2026022605570754800_keaf609-B8","article-title":"The profile of the COvid-19 VACcination register SAFEty study in Sweden (CoVacSafe-SE)","author":"Ljung","journal-title":"Ups J Med Sci"},{"key":"2026022605570754800_keaf609-B9","author":"Norwegian Institute of Public Health"},{"key":"2026022605570754800_keaf609-B10","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1001\/jamacardio.2022.0583","article-title":"SARS-CoV-2 vaccination and myocarditis in a nordic cohort study of 23 million residents","volume":"7","author":"Karlstad","year":"2022","journal-title":"JAMA Cardiol"},{"key":"2026022605570754800_keaf609-B11","first-page":"316","article-title":"Increased rates of idiopathic inflammatory myopathies during the COVID-19 pandemic: a single-centre experience","volume":"41","author":"Kharouf","year":"2023","journal-title":"Clin Exp Rheumatol"},{"key":"2026022605570754800_keaf609-B12","doi-asserted-by":"crossref","first-page":"126629","DOI":"10.1016\/j.vaccine.2024.126629","article-title":"Risk of adverse events after Omicron XBB-adapted BNT162b2 COVID-19 vaccination in the United States","volume":"45","author":"Sun","year":"2025","journal-title":"Vaccine"},{"key":"2026022605570754800_keaf609-B13","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1002\/pds.4788","article-title":"Change in risk for narcolepsy over time and impact of definition of onset date following vaccination with AS03 adjuvanted pandemic A\/H1N1 influenza vaccine (Pandemrix) during the 2009 H1N1 influenza pandemic","volume":"28","author":"Granath","year":"2019","journal-title":"Pharmacoepidemiol Drug Saf"}],"container-title":["Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/rheumatology\/advance-article-pdf\/doi\/10.1093\/rheumatology\/keaf609\/65482468\/keaf609.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumatology\/article-pdf\/65\/2\/keaf609\/65482468\/keaf609.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumatology\/article-pdf\/65\/2\/keaf609\/65482468\/keaf609.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T10:57:12Z","timestamp":1772103432000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/rheumatology\/article\/doi\/10.1093\/rheumatology\/keaf609\/8340427"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,22]]},"references-count":13,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2,4]]}},"URL":"https:\/\/doi.org\/10.1093\/rheumatology\/keaf609","relation":{},"ISSN":["1462-0324","1462-0332"],"issn-type":[{"value":"1462-0324","type":"print"},{"value":"1462-0332","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,2]]},"published":{"date-parts":[[2025,11,22]]},"article-number":"keaf609"}}